triazoles has been researched along with Bone Loss, Perimenopausal in 32 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 17 (53.13) | 29.6817 |
| 2010's | 15 (46.88) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ali, SM; Budd, GT; Chapman, JW; Elliott, CR; Ellis, MJ; Garg, A; Goss, PE; Han, L; Ingle, JN; Leitzel, K; Lipton, A; Pritchard, KI; Rabaglio, M; Shepherd, LE; Sledge, GW | 1 |
| Hadji, P; Hars, O; Kalder, M; Knöll, D; Kyvernitakis, I; Ziller, V | 1 |
| Aebi, S; Campone, M; Coates, AS; Debled, M; Decensi, A; Gelber, RD; Goldhirsch, A; Guerrieri-Gonzaga, A; Johansson, H; McIntosh, C; Monnier, A; Price, KN; Schönenberger, A; Sun, Z; Thürlimann, B; Tondini, C; Zaman, K | 1 |
| Hegazy, SK | 1 |
| Dakhil, SR; Hines, SL; Kearns, AE; Lafky, JM; Liu, H; Loprinzi, CL; Perez, EA; Puttabasavaiah, S; Sloan, JA; Wagner-Johnston, ND | 1 |
| Brufsky, A; Bundred, N; Coleman, R; Ericson, S; Hadji, P; Jin, L; Lambert-Falls, R; Mena, R; Perez, EA; Schenk, N | 1 |
| Cuzick, J | 1 |
| Alberts, S; Dentchev, T; Hines, SL; Johnson, DB; Kahanic, S; Liu, H; Loprinzi, CL; Mazurczak, MA; Mincey, B; Nikcevich, DA; Perez, EA; Schaefer, PL; Sloan, JA | 1 |
| Bosserman, LD; Brufsky, AM; Caradonna, RR; Ericson, SG; Haley, BB; Jin, L; Jones, CM; Moore, HC; Perez, EA; Warsi, GM | 1 |
| Botteman, MF; Heeg, BMS; Kaura, S; Logman, JFS; van Hout, BA | 1 |
| Apffelstaedt, JP; Barlow, D; Campone, M; Clack, G; Eastell, R; Hannon, RA; Mackey, JR; Makris, A; Van Poznak, C | 1 |
| Antonopoulou, Z; Dafni, U; Gogas, H; Kalogerakos, K; Koukouras, D; Lazarou, S; Markopoulos, C; Misitzis, J; Papadiamantis, J; Polychronis, A; Sarantopoulou, A; Siasos, N; Tzoracoleftherakis, E; Venizelos, B; Xepapadakis, G; Zobolas, V | 1 |
| Tang, SC | 1 |
| Cochrane, RA; Davie, MW; Powell, DE | 1 |
| Argonza-Aviles, E; Beck, JT; Bosserman, L; Brufsky, AM; Ericson, SG; Harker, WG; Hohneker, J; Jin, L; Perez, EA; Seidler, C; Vogel, C; Warsi, G | 1 |
| Deleu, I; Frassoldati, A; Jerusalem, G; Llombart, A; Mebis, J; Miller, J; Neven, P; Paija, O; Schenk, N; Sleeboom, HP | 1 |
| Bernstein-Molho, R; Geffen, DB; Greenberg, J; Inbar, MJ; Pelles-Avraham, S; Safra, T; Sarid, D; Stemmer, SM; Stephansky, I | 1 |
| Basso, U; Berton, L; Brunello, A; Coin, A; Falci, C; Manzato, E; Monfardini, S; Perissinotto, E; Pintore, G; Sergi, G; Veronese, N | 1 |
| Gogas, H; Koukouras, D; Markopoulos, C; Misitzis, J; Tzoracoleftherakis, E; Venizelos, B; Xepapadakis, G; Zobolas, V | 1 |
| Vervaeren, J | 1 |
| Esteva, FJ; Hortobagyi, GN | 1 |
| Aapro, M | 1 |
| Michaud, LB | 1 |
| Higa, GM | 1 |
| Chien, AJ; Goss, PE | 1 |
| Beck, JT; Brufsky, A; Carroll, R; Harker, WG; Hohneker, J; Lacerna, L; Perez, EA; Petrone, S; Seidler, C; Tan-Chiu, E | 1 |
| Galid, A; Gnant, MF; Grampp, S; Hausmaninger, H; Jakesz, R; Kaessmann, H; Luschin-Ebengreuth, G; Menzel, C; Mittlboeck, M; Mlineritsch, B; Piswanger-Soelkner, JC; Schmid, M | 1 |
| Brun, J; Confavreux, CB; Delmas, PD; Fontana, A; Guastalla, JP; Munoz, F | 1 |
| Bundred, NJ; Campbell, ID; Coleman, RE; Davidson, N; DeBoer, RH; Eidtmann, H; Miller, JC; Monnier, A; Neven, P; Schenk, NL; von Minckwitz, G | 1 |
| Chapman, JA; Goss, PE; Ingle, JN; Meng, D; Muss, HB; Palmer, M; Parulekar, W; Shepherd, L; Yu, C | 1 |
| Panasci, LC | 1 |
| Heshmati, HM; Khosla, S; Melton, LJ; O'Fallon, WM; Riggs, BL; Robins, SP | 1 |
4 review(s) available for triazoles and Bone Loss, Perimenopausal
| Article | Year |
|---|---|
Women and bone health: maximizing the benefits of aromatase inhibitor therapy.
Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Breast Neoplasms; Colorectal Neoplasms; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Letrozole; Nitriles; Osteoporosis; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic; RANK Ligand; Secondary Prevention; Tamoxifen; Triazoles; Zoledronic Acid | 2010 |
Comparative assessment of lipid effects of endocrine therapy for breast cancer: implications for cardiovascular disease prevention in postmenopausal women.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Estradiol; Female; Fulvestrant; Hormone Replacement Therapy; Humans; Lipids; Middle Aged; Nitriles; Osteoporosis, Postmenopausal; Risk Factors; Tamoxifen; Triazoles; Triglycerides | 2006 |
Improving bone health in patients with early breast cancer by adding bisphosphonates to letrozole: the Z-ZO-E-ZO-FAST program.
Topics: Aromatase Inhibitors; Bone Density; Breast Neoplasms; Diphosphonates; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Imidazoles; Letrozole; Nitriles; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic; Triazoles; Zoledronic Acid | 2006 |
Aromatase inhibitors and bone health in women with breast cancer.
Topics: Absorptiometry, Photon; Algorithms; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Remodeling; Breast Neoplasms; Diphosphonates; Female; Fractures, Bone; Humans; Life Style; Neoplasms, Hormone-Dependent; Nitriles; Osteoporosis, Postmenopausal; Population Surveillance; Risk Factors; Triazoles | 2006 |
19 trial(s) available for triazoles and Bone Loss, Perimenopausal
| Article | Year |
|---|---|
Osteoporosis therapy and outcomes for postmenopausal patients with hormone receptor-positive breast cancer: NCIC CTG MA.27.
Topics: Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Disease-Free Survival; Female; Humans; Male; Mastectomy; Middle Aged; Multivariate Analysis; Nitriles; Osteoporosis, Postmenopausal; Proportional Hazards Models; Radiotherapy, Adjuvant; Receptors, Estrogen; Treatment Outcome; Triazoles | 2017 |
Influence of compliance on bone mineral density changes in postmenopausal women with early breast cancer on Anastrozole.
Topics: Absorptiometry, Photon; Aged; Anastrozole; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Femur; Humans; Lumbar Vertebrae; Middle Aged; Nitriles; Osteoporosis, Postmenopausal; Patient Compliance; Postmenopause; Receptors, Steroid; Time Factors; Treatment Outcome; Triazoles | 2013 |
Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences.
Topics: Aged; Alkaline Phosphatase; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Bone Density; Breast Neoplasms; Chemotherapy, Adjuvant; Collagen Type I; Double-Blind Method; Drug Administration Schedule; Female; Humans; Letrozole; Middle Aged; Nitriles; Osteocalcin; Osteoporosis, Postmenopausal; Peptides; Postmenopause; Prospective Studies; Tamoxifen; Triazoles | 2014 |
Evaluation of the anti-osteoporotic effects of metformin and sitagliptin in postmenopausal diabetic women.
Topics: Absorptiometry, Photon; Aged; Alkaline Phosphatase; Amino Acids; Bone and Bones; Bone Density; Bone Diseases, Metabolic; Diabetes Mellitus; Female; Humans; Hypoglycemic Agents; Lumbar Vertebrae; Metformin; Middle Aged; Osteocalcin; Osteogenesis; Osteoporosis, Postmenopausal; Postmenopause; Pyrazines; Sitagliptin Phosphate; Triazoles | 2015 |
5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial.
Topics: Aged; Antineoplastic Agents; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Breast Neoplasms, Male; Chemotherapy, Adjuvant; Diphosphonates; Disease Progression; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Imidazoles; Letrozole; Male; Middle Aged; Nitriles; Osteoporosis, Postmenopausal; Postmenopause; Tamoxifen; Triazoles; Zoledronic Acid | 2015 |
Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole.
Topics: Adult; Aged; Aged, 80 and over; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Drug Administration Schedule; Female; Humans; Imidazoles; Letrozole; Lumbar Vertebrae; Middle Aged; Nitriles; Osteoporosis, Postmenopausal; Triazoles; Zoledronic Acid | 2008 |
Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Drug Administration Schedule; Female; Humans; Imidazoles; Letrozole; Middle Aged; Nitriles; Osteoporosis, Postmenopausal; Tamoxifen; Triazoles; Zoledronic Acid | 2009 |
Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results.
Topics: Adult; Aged; Aged, 80 and over; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Letrozole; Middle Aged; Neoplasm Staging; Nitriles; Osteoporosis, Postmenopausal; Prognosis; Survival Rate; Treatment Outcome; Triazoles; Zoledronic Acid | 2009 |
Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial.
Topics: Aged; Anastrozole; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Double-Blind Method; Etidronic Acid; Female; Fractures, Bone; Hormone Replacement Therapy; Humans; Middle Aged; Neoplasm Staging; Nitriles; Osteoporosis, Postmenopausal; Postmenopause; Prognosis; Risedronic Acid; Survival Rate; Treatment Outcome; Triazoles | 2010 |
Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial.
Topics: Administration, Oral; Aged; Anastrozole; Aromatase Inhibitors; Arthralgia; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Drug Therapy, Combination; Dyspepsia; Etidronic Acid; Female; Humans; Middle Aged; Nausea; Nitriles; Osteoporosis, Postmenopausal; Patient Dropouts; Prospective Studies; Risedronic Acid; Risk Factors; Time Factors; Treatment Outcome; Triazoles | 2010 |
Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents; Bone and Bones; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Letrozole; Middle Aged; Nitriles; Organ Size; Osteoporosis, Postmenopausal; Postmenopause; Triazoles; Zoledronic Acid | 2012 |
Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-month analysis of the E-ZO-FAST trial.
Topics: Adult; Aged; Aged, 80 and over; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Imidazoles; Letrozole; Middle Aged; Nitriles; Osteoporosis, Postmenopausal; Receptors, Estrogen; Treatment Outcome; Triazoles; Zoledronic Acid | 2012 |
The protective effect of zoledronic acid on bone loss in postmenopausal women with early breast cancer treated with sequential tamoxifen and letrozole: a prospective, randomized, phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Imidazoles; Letrozole; Middle Aged; Neoplasm Staging; Nitriles; Osteoporosis, Postmenopausal; Prospective Studies; Tamoxifen; Triazoles; Zoledronic Acid | 2011 |
Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer.
Topics: Adult; Aged; Alkaline Phosphatase; Bone Density; Breast Neoplasms; Collagen Type I; Diphosphonates; Female; Humans; Imidazoles; Letrozole; Middle Aged; Nitriles; Osteoporosis, Postmenopausal; Peptides; Triazoles; Zoledronic Acid | 2007 |
Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group.
Topics: Adult; Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Diphosphonates; Female; Goserelin; Humans; Imidazoles; Middle Aged; Nitriles; Osteoporosis, Postmenopausal; Tamoxifen; Triazoles; Zoledronic Acid | 2007 |
Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Breast Neoplasms; Collagen Type I; Diphosphonates; Estradiol; Female; Fractures, Bone; Humans; Middle Aged; Nitriles; Osteocalcin; Osteoporosis, Postmenopausal; Postmenopause; Triazoles | 2007 |
Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Drug Administration Schedule; Female; Humans; Imidazoles; Letrozole; Lumbar Vertebrae; Middle Aged; Nitriles; Osteoporosis, Postmenopausal; Triazoles; Zoledronic Acid | 2008 |
Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer.
Topics: Age Factors; Aged; Antineoplastic Agents, Hormonal; Breast Neoplasms; Canada; Cardiovascular Diseases; Cause of Death; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Female; Follow-Up Studies; Humans; Letrozole; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Osteoporosis, Postmenopausal; Prospective Studies; Receptors, Estrogen; Receptors, Progesterone; Research Design; Risk Factors; Triazoles | 2008 |
Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women.
Topics: Aged; Aromatase Inhibitors; Bone Remodeling; Bone Resorption; Double-Blind Method; Enzyme Inhibitors; Estradiol; Estrogens; Estrone; Female; Humans; Letrozole; Menopause; Middle Aged; Nitriles; Osteoporosis, Postmenopausal; Prospective Studies; Triazoles | 2002 |
9 other study(ies) available for triazoles and Bone Loss, Perimenopausal
| Article | Year |
|---|---|
IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole.
Topics: Adult; Aged; Anastrozole; Aromatase Inhibitors; Bone Density Conservation Agents; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Chemotherapy, Adjuvant; Double-Blind Method; Etidronic Acid; Female; Humans; Middle Aged; Multicenter Studies as Topic; Neoplasms, Hormone-Dependent; Nitriles; Osteoporosis, Postmenopausal; Postmenopause; Randomized Controlled Trials as Topic; Risedronic Acid; Triazoles | 2008 |
Economic evaluation of zoledronic acid for the prevention of osteoporotic fractures in postmenopausal women with early-stage breast cancer receiving aromatase inhibitors in the UK.
Topics: Aged; Aged, 80 and over; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Cohort Studies; Cost-Benefit Analysis; Diphosphonates; Female; Humans; Imidazoles; Letrozole; Markov Chains; Middle Aged; Neoplasm Staging; Nitriles; Osteoporosis, Postmenopausal; Quality-Adjusted Life Years; Salvage Therapy; Survival Rate; Treatment Outcome; Triazoles; Zoledronic Acid | 2010 |
Does anastrozole affect bone resorption similarly in early and late postmenopausal women?
Topics: Age Factors; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Bone Density; Bone Resorption; Breast Neoplasms; Carcinoma; Case-Control Studies; Collagen Type I; Cross-Sectional Studies; Female; Humans; Middle Aged; Nitriles; Osteoporosis, Postmenopausal; Peptides; Postmenopause; Risk Factors; Triazoles | 2011 |
Preventive effect of risedronate on bone loss and frailty fractures in elderly women treated with anastrozole for early breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Resorption; Breast Neoplasms; Calcium Carbonate; Cohort Studies; Combined Modality Therapy; Dietary Supplements; Etidronic Acid; Female; Follow-Up Studies; Humans; Neoplasm Staging; Nitriles; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Risedronic Acid; Severity of Illness Index; Triazoles; Vitamin D | 2012 |
Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trial.
Topics: Absorptiometry, Photon; Age Factors; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neoplasms; Drug Therapy, Combination; Etidronic Acid; Female; Humans; Middle Aged; Nitriles; Osteoporosis; Osteoporosis, Postmenopausal; Outcome and Process Assessment, Health Care; Prospective Studies; Randomized Controlled Trials as Topic; Risedronic Acid; Risk Assessment; Risk Factors; Time Factors; Triazoles | 2012 |
[Some new drugs: valdecoxib (Betra), voriconazole (Vfend), ezetimide (Ezetrol), teriparatide (Forsteo)].
Topics: Antifungal Agents; Azetidines; Cyclooxygenase Inhibitors; Ezetimibe; Female; Humans; Hypolipidemic Agents; Isoxazoles; Osteoporosis, Postmenopausal; Pyrimidines; Sulfonamides; Teriparatide; Triazoles; Voriconazole | 2004 |
Letrozole in postmenopausal hormone-responsive early-stage breast cancer : a viewpoint by Laura B. Michaud.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Cardiovascular Diseases; Chemotherapy, Adjuvant; Clinical Trials as Topic; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Osteoporosis, Postmenopausal; Postmenopause; Triazoles | 2006 |
Letrozole in postmenopausal hormone-responsive early-stage breast cancer: a viewpoint by Gerald M. Higa.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease-Free Survival; Female; Humans; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Osteoporosis, Postmenopausal; Postmenopause; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2006 |
Aromatase inhibitors: treatment of advanced breast cancer.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Female; Humans; Letrozole; Middle Aged; Nitriles; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic; Triazoles | 2001 |